Information Provided By:
Fly News Breaks for March 29, 2017
INNL
Mar 29, 2017 | 13:29 EDT
JMP Securities analyst Jason Butler upgraded Innocoll to Outperform with a $4 price target after the company announced this morning that it has received formal Type A Meeting minutes from the FDA relating to its New Drug Application for Xaracoll and believes required studies may be completed in time for a resubmission of the NDA at the end of 2017.
News For INNL From the Last 2 Days
There are no results for your query INNL